Genetic Engineering & Biotechnology News

NOV1 2018

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link:

Contents of this Issue


Page 56 of 57

The Cell Culture Revolution: Commercializing Therapeutic Cell Systems The advent of recombinant antibody production in mammalian cell lines has revolutionized modern medicine. Clinical success of these agents has challenged the underlying biological manufacturing systems to produce quantities sufficient to supply the ever-expanding commercial markets. A fundamental focus for commercialization efforts was optimization of cell culture media components utilized in the biologic manufacturing process. With primary and stem cell applications poised to make similar strides in clinical progress as monoclonal antibodies did in the 1990s, manufacturing methodologies must progress in parallel to ensure the clinical success of these novel cell-based therapeutics. In this GEN webinar, we will discuss the current state of the cell culture media space for primary and stem cell expansion. Moreover, we will discuss the reagents and development strategies needed to remove serum-derived proteins from media formulations to produce chemically defined and blood component free, or blood-free, expansion processes for therapeutic cell types. A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist. Free Registration! View It Now On Demand DURATION: 45 minutes COST: Complimentary Speaker Randall Alfano, Ph.D. Vice President of Product Development InVitria Produced with support from Webinars

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - NOV1 2018